| Search by tag or site | Login to my blog ? Start my own blog |
 |
BioHealth InvestorBioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network. |
Cancer Stocks - Weekly Review
Posted on 06/04/2007 15:14:23 | Link | Post Comment
by Alan J. Brochstein, CFA
Analyst For Hire
Cancer-related stocks soared during this holiday-shortened week as presentations began on June 1st at the ASCO annual meeting in Chicago. Last week’s big winner, Bioenvision (BIVN) received an offer from partner Genzyme at a disappointing premium but well ahead of multi-year lows reached in early May. The list below is comprised of domestic companies primarily with market caps in excess of $50mm, ranked by the return this past week. If the reader believes that there are erroneous inclusions or exclusions, feel free to let me know.
As one can see, 19 of the 89 stocks, or over 20%, produced double-digit returns, with just one double-digit decline. The average return of 5.1% was 3.7% ahead of the S&P 500, while the median of 2.0% was ahead of the market as well. Looking at the one big loser, Inovio (INO), shares pulled back after reaching a 52 week high in the prior week. The stock remains in a solid uptrend and held the 3.52 level at which they sold stock in Mid-May. The company specializes in vaccine delivery technology as well as electro-chemotherapy (MedPulser).
5 stocks rallied in excess of 20%, including Novacea (NOVC), which cut a deal with partner Schering-Plough (SGP) to develop a late-stage prostate cancer treatment. The stock surged on the week despite pulling back a couple of points on downgrades. Vion (VION) bounced back a bit after getting clobbered in the prior week (ended an AML trial). Dendreon (DNDN) surged on news that the FDA would accept partial data (perhaps shortening time to market). Peregrine (PPHM) rallied from close to a 52-week low but remained below the declining 200dma as it reported data from a Phase 1b trial. Finally, Poniard (PARD), which is developing a next-generation platinum agent, surged on Phase 1 data as well. The stock looks very strong technically, moving to a 52 week high on its highest volume ever.
Source: AnalystForHire.com
RELATED READING:
- Cancer Stocks on the Go: It’s ASCO
___________________
Analyst For Hire
Cancer-related stocks soared during this holiday-shortened week as presentations began on June 1st at the ASCO annual meeting in Chicago. Last week’s big winner, Bioenvision (BIVN) received an offer from partner Genzyme at a disappointing premium but well ahead of multi-year lows reached in early May. The list below is comprised of domestic companies primarily with market caps in excess of $50mm, ranked by the return this past week. If the reader believes that there are erroneous inclusions or exclusions, feel free to let me know.
As one can see, 19 of the 89 stocks, or over 20%, produced double-digit returns, with just one double-digit decline. The average return of 5.1% was 3.7% ahead of the S&P 500, while the median of 2.0% was ahead of the market as well. Looking at the one big loser, Inovio (INO), shares pulled back after reaching a 52 week high in the prior week. The stock remains in a solid uptrend and held the 3.52 level at which they sold stock in Mid-May. The company specializes in vaccine delivery technology as well as electro-chemotherapy (MedPulser).
5 stocks rallied in excess of 20%, including Novacea (NOVC), which cut a deal with partner Schering-Plough (SGP) to develop a late-stage prostate cancer treatment. The stock surged on the week despite pulling back a couple of points on downgrades. Vion (VION) bounced back a bit after getting clobbered in the prior week (ended an AML trial). Dendreon (DNDN) surged on news that the FDA would accept partial data (perhaps shortening time to market). Peregrine (PPHM) rallied from close to a 52-week low but remained below the declining 200dma as it reported data from a Phase 1b trial. Finally, Poniard (PARD), which is developing a next-generation platinum agent, surged on Phase 1 data as well. The stock looks very strong technically, moving to a 52 week high on its highest volume ever.
Source: AnalystForHire.com
RELATED READING:
- Cancer Stocks on the Go: It’s ASCO
___________________
- Mri To Lead Growth In Medical-imaging Market
- Malaria And Hiv - Eradication And Treatment
- Dragon’s New Production Process To Cut Costs
- Mrsa Update: Cepheid, Basilea And Nektar
- If Only Us Health Care Could Be More Like The Patriots (or Even The Red Sox) And Less Like The Yankees
- Ludwig von Mises Institute
- Credit Bloggers
- Millionaire Now! by Larry Nusbaum
- Don't Mess With Taxes
- Poor and Stupid
Examples
Morpheus Trading - Sun Aug 24, 2008 06:22AM
NOTE: Please click on the charts below to enlarge them if [read more]
NOTE: Please click on the charts below to enlarge them if [read more]
Morpheus Trading - Thu Aug 28, 2008 02:39AM
NOTE: Please click on the charts below to enlarge them if [read more]
NOTE: Please click on the charts below to enlarge them if [read more]
Boucher On The Big Picture - Thu Aug 28, 2008 05:01PM
Market Needs to Show Volume and Breadth To Signal Next M [read more]
Market Needs to Show Volume and Breadth To Signal Next M [read more]
<< My Home | TheMoneyBlogs Home